Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal center and post germinal center B-cells.
Diffuse Large B-Cell Lymphoma Emerging Drugs
- Lisocabtagene maraleucel: Bristol-Myers Squibb
- Brentuximab Vedotin: Seattle Genetics/Takeda
- Loncastuximab Tesirine: ADC Therapeutics
- Tafasitamab: Morphosys/Incyte
- Treakisym: SymBio Pharmaceuticals
- Enzastaurin (DB102): Denovo Biopharma
- Ublituximab + Umbralisib: TG Therapeutics
- Blinatumomab: Amgen
- Aliqopa (Copanlisib/BAY 80-6946): Bayer
- Imbruvica (Ibrutinib): Janssen/Pharmacyclics (AbbVie Company)
- Odronextamab (REGN1979): Regeneron Pharmaceuticals
- Imfinzi (durvalumab): Celgene/Bristol Myers Squibb
- Parsaclisib (INCB050465): Incyte Corporation
- TC 110: TCR2 Therapeutics
- DPX-Survivac: IMV, inc. & Merck
- Acalabrutinib: AstraZeneca
- AUTO3: Autolus Therapeutics
- Obinutuzumab: Hoffmann-La Roche
- CLR 131: Cellectar Bioscience
- Debio1562: Debiopharm International
The dynamics of the DLBCL therapeutic market is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as MorphoSys, Cellectar, ADC Therapeutics, and others are involved in developing drugs for DLBCL.
MOR208 (MorphoSys) also known as Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19, which is assumed to be involved in B cell receptor (BCR) signaling. MorphoSys is clinically investigating MOR208 as a therapeutic option in B cell malignancies in several combination trials. The MOR208 in combination with lenalidomide; bendamustine is being investigated individually in patients with relapsed/refractory DLBCL who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) in the phase II/III trial. Based on interim data from L-MIND study, the FDA granted Breakthrough Therapy Designation for MOR208 plus lenalidomide in this patient population. Along with this, Orphan drug designation was received for MOR208 for the indications of DLBCL and CLL/SLL from FDA and EMA.
ADCT-402 (ADC Therapeutics) also known as loncastuximab tesirine is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody that binds to human CD19, conjugated through a linker to a pyrrolobenzodiazepine (PBD)-dimer toxin. CD19 is an ideal target for an ADC approach, as it is highly expressed in a range of B-cell hematological tumors, including certain types of lymphoma and leukemia. Once bound to a CD19-expressing cell, it internalized into the cell where enzymes release the PBD-based warhead. The FDA has granted orphan drug designation to ADCT-402 for the treatment of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). The ADC Therapeutics is currently conducting Phase II clinical trial in patients with relapsed or refractory (R/R), Phase I trial in combination with ibrutinib; and durvalumab in patients with R/R DLBCL or follicular lymphoma and melanoma.
Selinexor (Karyopharm Therapeutics) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound and functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. The FDA granted Fast Track designation to Selinexor for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies and are not eligible for high dose chemotherapy with stem cell rescue or CAR-T therapy. FDA has granted Selinexor orphan designation for both multiple myeloma and DLBCL.
CLR 131 (Cellectar) is a small-molecule, targeted Phospholipid Drug Conjugate (PDC) designed to deliver cytotoxic radiation directly and selectively to cancer cells. It is a lead therapeutic PDC product candidate of Cellectar. Currently, company is conducting the Phase II trial for the treatment of Diffuse Large B Cell Lymphoma and other indications such as Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and others.
Scope of the report
- The Diffuse Large B-cell Lymphoma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Diffuse Large B-cell Lymphoma across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Diffuse Large B-cell Lymphoma therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Diffuse Large B-cell Lymphoma research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Diffuse Large B-cell Lymphoma.
Request for sample pages
Table of contents
1. Report Introduction
2. Diffuse Large B-cell Lymphoma
2.1. Overview
2.2. History
2.3. Diffuse Large B-cell Lymphoma Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Diffuse Large B-cell Lymphoma Diagnosis
2.6.1. Diagnostic Guidelines
3. Diffuse Large B-cell Lymphoma Current Treatment Patterns
3.1. Diffuse Large B-cell Lymphoma Treatment Guidelines
4. Diffuse Large B-cell Lymphoma – DelveInsight’s Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Diffuse Large B-cell Lymphoma companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Diffuse Large B-cell Lymphoma Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Diffuse Large B-cell Lymphoma Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Diffuse Large B-cell Lymphoma Late Stage Products (Phase-III)
7. Diffuse Large B-cell Lymphoma Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Diffuse Large B-cell Lymphoma Discontinued Products
13. Diffuse Large B-cell Lymphoma Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Diffuse Large B-cell Lymphoma Key Companies
15. Diffuse Large B-cell Lymphoma Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Diffuse Large B-cell Lymphoma Unmet Needs
18. Diffuse Large B-cell Lymphoma Future Perspectives
19. Diffuse Large B-cell Lymphoma Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/